Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan

International Journal of Pharmaceutics

Volumn 443, Issue 1-2, 2013, Pages 17-25

  Li, Chunlei ^a,b,c,d   Zhao, Xi ^b,c,d   Wang, Yajuan ^b,c,d   Yang, Hanyu ^b,c,d   Li, Haixia ^b,c,d   Li, Huan ^b,c,d   Tian, Wei ^a   Yang, Jian ^b,c,d   Cui, Jingxia ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

^c Hebei Pharmaceutical Engineering and Technology Research Center   (China)

^d State Key Lab of Novel Pharmaceutical Preparations and Excipients   (China)

Author keywords

Accelerated blood clearance; Pegylated liposomes; Repeated injection; Time interval; Topotecan

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN M; LIPOSOME; TOPOTECAN;

ACCELERATED BLOOD CLEARANCE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; LIPID VESICLE; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG COMPOUNDING; IMMUNOGLOBULIN M; INFUSIONS, INTRAVENOUS; LIPOSOMES; METABOLIC CLEARANCE RATE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE PROPERTIES; TIME FACTORS; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84873043783     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.01.012     Document Type: Article

References (21)

1. T.M. Allen Long-circulating (sterically stabilized) liposomes for targeted drug delivery Trends Pharmacol. Sci. 15 1994 215 220
2. T.M. Allen Liposomal drug formulations. Rationale for development and what we can expect for the future Drugs 56 1998 747 756
3. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822
4. T.M. Allen, W.W. Cheng, J.I. Hare, and K.M. Laginha Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer Anticancer Agents Med. Chem. 6 2006 513 523
5. T.M. Allen, C. Hansen, F. Martin, C. Redemann, and A. Yau-Young Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo Biochim. Biophys. Acta 1066 1991 29 36
6. G.J. Charrois, and T.M. Allen Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity J. Pharmacol. Exp. Ther. 306 2003 1058 1067
7. I. Cheong, X. Huang, C. Bettegowda, L.A. Diaz Jr., K.W. Kinzler, S. Zhou, and B. Vogelstein A bacterial protein enhances the release and efficacy of liposomal cancer drugs Science 314 2006 1308 1311
8. J. Cui, C. Li, C. Wang, Y. Li, L. Zhang, L. Zhang, and H. Yang Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase J. Pharm. Pharmacol. 60 2008 1651 1657
9. J. Cui, C. Li, W. Guo, Y. Li, C. Wang, L. Zhang, L. Zhang, Y. Hao, and Y. Wang Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J. Control. Release 118 2007 204 215
10. E.T. Dams, P. Laverman, W.J. Oyen, G. Storm, G.L. Scherphof, J.W. van Der Meer, F.H. Corstens, and O.C. Boerman Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes J. Pharmacol. Exp. Ther. 292 2000 1071 1079
11. D.B. Fenske, and P.R. Cullis Liposomal nanomedicines Expert Opin. Drug Deliv. 5 2008 25 44
12. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436
13. G. Haran, R. Cohen, L.K. Bar, and Y. Barenholz Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1151 1993 201 215
14. T. Ishida, K. Atobe, X. Wang, and H. Kiwada Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection J. Control. Release 115 2006 251 258
15. T. Ishida, T. Ichikawa, M. Ichihara, Y. Sadzuka, and H. Kiwada Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice J. Control. Release 95 2004 403 412
16. P. Laverman, M.G. Carstens, O.C. Boerman, E.T. Dams, W.J. Oyen, N. van Rooijen, F.H. Corstens, and G. Storm Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection J. Pharmacol. Exp. Ther. 298 2001 607 612
17. C. Li, C. Wang, H. Yang, X. Zhao, N. Wei, and J. Cui Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity J. Pharm. Pharmacol 64 2012 372 382
18. Y. Ma, Q. Yang, L. Wang, X. Zhou, Y. Zhao, and Y. Deng Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats Eur. J. Pharm. Sci. 45 2012 539 545
19. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, and C. Redemann Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88 1991 11460 11464
20. X. Wang, T. Ishida, and H. Kiwada Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes J. Control. Release 119 2007 236 244
21. K. Yamamoto, Y. Mizutani, H. Nakanishi, J. Fujiwara, H. Ishida, D. Toiyama, K. Abe, I. Hayashi, K. Okada, A. Kawauchi, M. Mizuno, J. Yoshida, and T. Miki Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma Int. J. Oncol. 33 2008 565 571